Literature DB >> 17467922

Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.

David C Rice1, W Roy Smythe, Zhongxing Liao, Thomas Guerrero, Joe Y Chang, Mary F McAleer, Melenda D Jeter, Arlene Correa, Ara A Vaporciyan, H Helen Liu, Ritsuko Komaki, Kenneth M Forster, Craig W Stevens.   

Abstract

PURPOSE: To determine the incidence of fatal pulmonary events after extrapleural pneumonectomy and hemithoracic intensity-modulated radiotherapy (IMRT) for malignant pleural mesothelioma. METHODS AND MATERIALS: We retrospectively reviewed the records of 63 consecutive patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy and IMRT at the University of Texas M. D. Anderson Cancer Center. The endpoints studied were pulmonary-related death (PRD) and non-cancer-related death within 6 months of IMRT.
RESULTS: Of the 63 patients, 23 (37%) had died within 6 months of IMRT (10 of recurrent cancer, 6 of pulmonary causes [pneumonia in 4 and pneumonitis in 2], and 7 of other noncancer causes [pulmonary embolus in 2, sepsis after bronchopleural fistula in 1, and cause unknown but without pulmonary symptoms or recurrent disease in 4]). On univariate analysis, the factors that predicted for PRD were a lower preoperative ejection fraction (p = 0.021), absolute volume of lung spared at 10 Gy (p = 0.025), percentage of lung volume receiving >or=20 Gy (V(20); p = 0.002), and mean lung dose (p = 0.013). On multivariate analysis, only V20 was predictive of PRD (p = 0.017; odds ratio, 1.50; 95% confidence interval, 1.08-2.08) or non-cancer-related death (p = 0.033; odds ratio, 1.21; 95% confidence interval, 1.02-1.45).
CONCLUSION: The results of our study have shown that fatal pulmonary toxicities were associated with radiation to the contralateral lung. V20 was the only independent determinant for risk of PRD or non-cancer-related death. The mean V20 of the non-PRD patients was considerably lower than that accepted during standard thoracic radiotherapy, implying that the V20 should be kept as low as possible after extrapleural pneumonectomy.

Entities:  

Mesh:

Year:  2007        PMID: 17467922     DOI: 10.1016/j.ijrobp.2007.03.011

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  40 in total

Review 1.  Radiation dose-volume effects in the lung.

Authors:  Lawrence B Marks; Soren M Bentzen; Joseph O Deasy; Feng-Ming Spring Kong; Jeffrey D Bradley; Ivan S Vogelius; Issam El Naqa; Jessica L Hubbs; Joos V Lebesque; Robert D Timmerman; Mary K Martel; Andrew Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

2.  Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment.

Authors:  S Lorentini; M Amichetti; L Spiazzi; S Tonoli; S M Magrini; F Fellin; M Schwarz
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

3.  Novel radiation therapy approaches in malignant pleural mesothelioma.

Authors:  Andreas Rimner; Kenneth E Rosenzweig
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 4.  A review of intensity-modulated radiation therapy.

Authors:  Laurie E Gaspar; Meisong Ding
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

Review 5.  What is the role of radiotherapy in malignant pleural mesothelioma?

Authors:  Allan Price
Journal:  Oncologist       Date:  2011-02-23

6.  Stereotactic body radiation therapy for a new lung cancer arising after pneumonectomy: dosimetric evaluation and pulmonary toxicity.

Authors:  Alessandro Testolin; Maria Silvia Favretto; Stefania Cora; Carlo Cavedon
Journal:  Br J Radiol       Date:  2015-08-20       Impact factor: 3.039

Review 7.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

8.  Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.

Authors:  Andreas Rimner; Marjorie G Zauderer; Daniel R Gomez; Prasad S Adusumilli; Preeti K Parhar; Abraham J Wu; Kaitlin M Woo; Ronglai Shen; Michelle S Ginsberg; Ellen D Yorke; David C Rice; Anne S Tsao; Kenneth E Rosenzweig; Valerie W Rusch; Lee M Krug
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

9.  A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma.

Authors:  Stephanie R Rice; Yun R Li; Theresa M Busch; Michele M Kim; Sally McNulty; Andrea Dimofte; Timothy C Zhu; Keith A Cengel; Charles B Simone
Journal:  Photochem Photobiol       Date:  2018-12-28       Impact factor: 3.421

Review 10.  The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.

Authors:  Miranda Ashton; Noelle O'Rourke; Suzanne Currie; Andreas Rimner; Anthony Chalmers
Journal:  Radiother Oncol       Date:  2017-08-28       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.